Optimal summary of information in longitudinal CA125 measurements for efficient ovarian cancer screening

被引:0
|
作者
Skates, SJ [1 ]
机构
[1] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA
来源
JOURNAL OF CLINICAL LIGAND ASSAY | 2000年 / 23卷 / 02期
关键词
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Ovarian cancer mortality rates have changed little over 30 years despite therapeutic advances. Given the large proportion of cases discovered in late stages and consequent poor prognosis, and the excellent prognosis if discovered in early stages, screening is an appealing approach to investigate reducing ovarian cancer mortality, Due to the large scale of screening programs end the low incidence of ovarian cancer, it is paramount that the screening strategy is as efficient as possible. CA125 is a marker for ovarian cancer that shows promise in detecting most ovarian cancers preclinically. However, its efficiency could be substantially improved if longitudinal CA125 values were taken into account in the screening program, We provide a detailed description, with minimal mathematical notation, of a systematic statistical calculation to optimally summarize the information in longitudinal CA125 values. Based on this calculation we describe a strategy, called the risk of ovarian cancer algorithm (ROCA), which implements an efficient approach to screening for ovarian cancer based on longitudinal CA125 measurements.
引用
收藏
页码:150 / 154
页数:5
相关论文
共 50 条
  • [21] Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women
    Gentry-Maharaj, Aleksandra
    Blyuss, Oleg
    Ryan, Andy
    Burnell, Matthew
    Karpinskyj, Chloe
    Gunu, Richard
    Kalsi, Jatinderpal K.
    Dawnay, Anne
    Marino, Ines P.
    Manchanda, Ranjit
    Lu, Karen
    Yang, Wei-Lei
    Timms, John F.
    Parmar, Max
    Skates, Steven J.
    Bast, Robert C., Jr.
    Jacobs, Ian J.
    Zaikin, Alexey
    Menon, Usha
    CANCERS, 2020, 12 (07) : 1 - 12
  • [22] The role of CA 125 in screening for ovarian cancer
    Rosenthal, AN
    Jacobs, IJ
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1998, 13 (04): : 216 - 220
  • [23] Commentary on 'Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening'
    Wan, Y. L.
    Crosbie, E. J.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2014, 121 : 40 - 47
  • [24] CA125 as a predictive marker for optimal interval debulking surgery in advanced ovarian cancer.
    Furukawa, N.
    Shigetomi, H.
    Yoshida, S.
    Kawaguchi, R.
    Komeda, S.
    Tanase, Y.
    Yamada, Y.
    Kobayashi, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Prognostic value of serial CA125 measurements during chemotherapy for patients with advanced ovarian cancer
    Koper, NP
    Massuger, LFAG
    Thomas, CMG
    Kiemeney, LALM
    Schijf, CPT
    Beex, LVAM
    Verbeek, ALM
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1997, 7 (02) : 127 - 133
  • [26] Correlates of the preoperative level of CA125 at presentation of ovarian cancer
    Cramer, Daniel W.
    Vitonis, Allison F.
    Welch, William R.
    Terry, Kathryn L.
    Goodman, Annekathryn
    Rueda, Bo R.
    Berkowitz, Ross S.
    GYNECOLOGIC ONCOLOGY, 2010, 119 (03) : 462 - 468
  • [27] Combined inhibin and CA125 assays in the detection of ovarian cancer
    Robertson, DM
    Cahir, N
    Burger, HG
    Mamers, P
    McCloud, PI
    Pettersson, K
    McGuckin, M
    CLINICAL CHEMISTRY, 1999, 45 (05) : 651 - 658
  • [28] Nadir CA125 concentration as a prognostic indicator in ovarian cancer
    Baron, AT
    Maihle, N
    NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (06): : 288 - 289
  • [29] CA125 response to bevacizumab in recurrent ovarian cancer.
    O'Cearbhaill, R. E.
    Zhou, Q.
    Iasonos, A.
    Diaz, J. P.
    Tew, W. P.
    Hensley, M. L.
    O'Flaherty, C.
    Aghajanian, C.
    Spriggs, D. R.
    Sabbatini, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Nadir CA125 concentration as a prognostic indicator in ovarian cancer
    Andre T Baron
    Nita Maihle
    Nature Clinical Practice Oncology, 2005, 2 : 288 - 289